Optimised Post-discharge Care in Older Patients After Surgery for Colon Cancer (ERAS 3.0)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of the study is to investigate whether an extended program (ERAS 3.0) initiated hospital discharge, can improve recovery in elderly, frail patients who have undergone surgery for colon cancer. The study is a randomised controlled trial with two groups: an intervention group receiving the ERAS 3.0 program and a control group recieving standard care. The ERAS 3.0 program includes a comprehensive geriatric health assessment, dietary counseling from a dietitian, and instructions on training and physical activity. These activities will take place in the participant's homes after hospital discharge. Data will be collected at multiple time points: at the hospital, 12 days post-discharge (at the outpatient clinic), and at 1 and 3 months post discharge in the participants' homes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

• Age 65+

• Clinical Frailty Scale preoperative score 4-7

• Nutritional Risk Screening tool (NRS 2002) \> 3

• Elective colonic resection

• No stoma planned

• Minimally invasive surgical approach (laparoscopic or robotic)

• Patients discharged to own home

• Informed consent to participate

Locations
Other Locations
Denmark
University Hospital Herlev
RECRUITING
Herlev
University Hospital Herlev
NOT_YET_RECRUITING
Herlev
Contact Information
Primary
Elna A. Dalsgaard, ph.d. student
elna.adalsteinsdottir.dalsgaard@regionh.dk
+45 42402296
Backup
Jacob Rosenberg, Professor, dr.med.
jacob.rosenberg@regionh.dk
Time Frame
Start Date: 2025-04-01
Estimated Completion Date: 2029-12-20
Participants
Target number of participants: 60
Treatments
Experimental: ERAS 3.0 group
Post-surgery support at discharge and at home
No_intervention: Standard care group
Standard care, which is no support after discharge
Related Therapeutic Areas
Sponsors
Leads: Copenhagen University Hospital at Herlev
Collaborators: Danish Cancer Society

This content was sourced from clinicaltrials.gov